ABSTRACT
PURPOSE: The incidence and management of antitumoral compound extravasation that occurred in our medical day hospital unit were registered in a 10-year period. METHODS: A total of 114 episodes were consecutively recorded out of an estimated number of 211,948 administrations performed (0.05%). Type of compound, localization, timing, symptoms, treatment, resolution, or sequelae were documented. RESULTS: Extravasations after anthracyclines (17/114), platinum compounds (34/114), vinca alkaloids (7/114), and taxanes (34/114) were more frequently associated with edema and erythema ± pain. Five cases of monoclonal antibodies extravasation were observed without sequelae. With the involvement of an interdisciplinary task force and the use of dedicated guidelines, conservative management was successful in all patients. In the great majority of cases, recovery was complete within 48 hours after antidote administration. The support of our pharmacy was crucial. Physiatric evaluation was considered in several cases. No patients required surgery. CONCLUSIONS: We confirm that the adopted standardized approach to this event resulted in a satisfactory outcome and could be suggested as appropriate for managing extravasation in a large clinical context.
Subject(s)
Antidotes/administration & dosage , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Conservative Treatment/methods , Extravasation of Diagnostic and Therapeutic Materials/complications , Inflammation/chemically induced , Inflammation/therapy , Subcutaneous Tissue/drug effects , Ulcer/therapy , Adult , Aged , Anthracyclines/administration & dosage , Anthracyclines/adverse effects , Blister/chemically induced , Blister/therapy , Conservative Treatment/standards , Edema/chemically induced , Edema/therapy , Erythema/chemically induced , Erythema/therapy , Female , Humans , Incidence , Male , Middle Aged , Pain/chemically induced , Pain Management/methods , Platinum Compounds/administration & dosage , Platinum Compounds/adverse effects , Risk Factors , Subcutaneous Tissue/injuries , Subcutaneous Tissue/pathology , Taxoids/administration & dosage , Taxoids/adverse effects , Time Factors , Treatment Outcome , Ulcer/chemically induced , Vinca Alkaloids/administration & dosage , Vinca Alkaloids/adverse effectsABSTRACT
BACKGROUND: Acute hypersensitivity reactions are adverse events potentially associated with antineoplastic drug infusions. Their occurrence can be particularly relevant in an outpatient environment where time of administration and subsequent observation is limited to a short period of time. In addition, concern about the onset of more severe hypersensitivity reactions can limit subsequent use of crucial drugs. METHODS: During a 3-year observational period, we collected a total of 240 infusional acute hypersensitivity reactions out of 56,120 administrations performed, with an overall incidence of 0.4%. RESULTS: In order of frequency, platinum derivatives, taxanes and monoclonal antibodies accounted for the highest incidences. Their relative frequency was: oxaliplatin, 2.5%; carboplatin, 0.4%; paclitaxel, 1.2%; docetaxel, 1.2%; trastuzumab, 1.2%, and rituximab, 1.2%. CONCLUSIONS: Since the number of chemotherapeutic agents is steadily increasing, much attention should be paid to such reactions, particularly when several administrations are performed daily, and where management of the potential risk associated with specific drugs is mandatory. Their occurrence represents an unpredictable, unexpected and often hard to manage contingency, and our opinion is that observation and consciousness of this issue are fundamental for its appropriate management. We describe our experience, emphasizing the role of this toxicity and explaining how this awareness allowed us to define some empirical rules to handle acute hypersensitivity reactions.
Subject(s)
Antibodies, Monoclonal/adverse effects , Antineoplastic Agents/adverse effects , Drug Hypersensitivity/epidemiology , Drug Hypersensitivity/therapy , Platinum Compounds/adverse effects , Taxoids/adverse effects , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Murine-Derived/adverse effects , Antineoplastic Agents/administration & dosage , Carboplatin/adverse effects , Docetaxel , Drug Hypersensitivity/etiology , Drug Hypersensitivity/prevention & control , Female , Humans , Incidence , Infusions, Intravenous , Italy/epidemiology , Male , Middle Aged , Neoplasms/drug therapy , Organoplatinum Compounds/adverse effects , Oxaliplatin , Paclitaxel/adverse effects , Platinum Compounds/administration & dosage , Rituximab , Taxoids/administration & dosage , TrastuzumabABSTRACT
Oxaliplatin, a platinum analogue employed in the treatment of colorectal cancer and various other neoplasms, is characterized by a broad range of adverse events. Peripheral neuropathy is probably the most peculiar and clinically relevant toxicity associated with its use and can be distinguished into two types: acute and chronic neurotoxicity.We report a case of acute reversible bilateral palpebral ptosis and dyspnea without bronchospasm or laryngospasm which occurred at the end of the third administration of adjuvant oxaliplatin by infusion for stage III colon cancer in a 54-year-old woman. Chlorphenamine and hydrocortisone were administered with fast resolution of dyspnea and slight improvement of ptosis. Complete resolution with no sequelae occurred in one hour. No further recurrence of blepharoptosis was described during the following days. The subsequent cycles were prescribed at reduced dosage without acute complications.
